%0 Journal Article %A Xiaonan Liu %A Jennifer A Collister %A Thomas J Littlejohns %A Davide Morelli %A David A Clifton %A David J Hunter %A Lei Clifton %T Combining Machine Learning with Cox models for identifying risk factors for incident post-menopausal breast cancer in the UK Biobank %D 2022 %R 10.1101/2022.06.27.22276932 %J medRxiv %P 2022.06.27.22276932 %X Breast cancer is the most common cancer in women. A better understanding of risk factors plays a central role in disease prediction and prevention. We aimed to identify potential novel risk factors for breast cancer among post-menopausal women, with pre-specified interest in the role of polygenic risk scores (PRS) for risk prediction.We designed an analysis pipeline combining both machine learning (ML) and classical statistical models with emphasis on necessary statistical considerations (e.g. collinearity, missing data). Extreme gradient boosting (XGBoost) machine with Shapley (SHAP) feature importance measures were used for risk factor discovery among ~1.7k features in 104,313 post-menopausal women from the UK Biobank cohort. Cox models were constructed subsequently for in-depth investigation.Both PRS were significant risk factors when fitted simultaneously in both ML and Cox models (p < 0.001). ML analyses identified 11 (excluding the two PRS) novel predictors, among which five were confirmed by the Cox models: plasma urea (HR=0.95, 95% CI 0.92−0.98, p < 0.001) and plasma phosphate (HR=0.67, 95% CI 0.52−0.88, p = 0.003) were inversely associated with risk of developing post-menopausal breast cancer, whereas basal metabolic rate (HR=1.15, 95% CI 1.08−1.22, p < 0.001), red blood cell count (HR=1.20, 95% CI 1.08−1.34, p = 0.001), and creatinine in urine (HR=1.05, 95% CI 1.01−1.09, p = 0.008) were positively associated.Our final Cox model demonstrated a slight improvement in risk discrimination when adding novel features to a simpler Cox model containing PRS and the established risk factors (Harrell’s C-index = 0.670 vs 0.665).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UK Biobank study was supported by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also received funding from the Welsh Assembly government and British Heart Foundation. This research was conducted using the UK Biobank Resource under Application Number 33952. The analyses here were funded by the Cancer Research UK (grant no C16077/A29186), and supported by the Nuffield Department of Population Health, Oxford University. DAC declares academic grants from GlaxoSmithKline and personal fees from Oxford University Innovation, Biobeats and Sensyne Health, outside the context of this work. DAC is additionally supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The North West Multi-center Research Ethics Committee gave ethical approval for the UK Biobank study (REC reference: 11/NW/03820). All participants gave written informed consent before enrolment in the study, which was conducted in accordance with the principles of the Declaration of Helsinki. This study has been conducted under the UK Biobank application ID 33952.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in this paper are available via application directly to the UK Biobank, https://www.ukbiobank.ac.uk. The code used for analyses are available at https://github.com/xiaonanl1996/MLforBrCa. https://github.com/xiaonanl1996/MLforBrCa %U https://www.medrxiv.org/content/medrxiv/early/2022/06/27/2022.06.27.22276932.full.pdf